Biomerica, Inc. (BMRA, Financial) has secured approval from the United Arab Emirates' Ministry of Health and Prevention for its Fortel Ulcer Test. This latest sanction opens the door for the company to distribute its rapid point-of-care test for Helicobacter pylori infection throughout the UAE, a nation grappling with rising cases of gastrointestinal diseases.
The Fortel Ulcer Test is designed to assist healthcare professionals in swiftly identifying H. pylori infections, allowing for timely interventions to avert severe gastrointestinal conditions, including cancer. This approval is part of Biomerica's strategy to enhance healthcare outcomes within the region by providing tools that enable earlier detection and treatment of prevalent health issues.
